Galatan Vlad

Radiation oncologist

[ESTRO @ESTRO_RT]

The #UpperGI ESTRO Focus Group has released its comprehensive digest from #ESTRO26, capturing pivotal updates across oesophageal, gastric, pancreatic, and biliary tract cancers.
👉 https://t.co/CZjzaWfdcO

#Radonc #GICancer #radiotherapy #CongressReport #CancerResearch #SBRT

[ESTRO @ESTRO_RT]

ESTRO recommendations for the use, planning and delivery of #reirradiation in locally recurrent #rectalcancer, endorsed by @ASTRO_org. Published in the #GreenJournal.
👉 https://t.co/xzCsZQeRmV
#radiotherapy #radonc #guidelines

[Jeff Ryckman @jryckman3]

1/
New in Radiotherapy & Oncology:
ESTRO consensus recommendations on how to focal boost the intraprostatic tumour in prostate cancer.

The practical question: now that FLAME is positive, who gets a boost, how do we contour it, and what dose do we prescribe?

Why it matters: focal boosting is about to become a lot more common.

[Alessio Cortellini @ACortelliniMD]

Very proud to share our paper in @TheLancetOncol
Using the randomized #PACIFIC trial, we provide the first evidence that microbiota-modifying medications may influence immunotherapy benefit in a curative-intent/early-stage setting.
Years of work, brilliantly led by @Brunet3Leon. Huge thanks to @derosa__lisa and her outstanding team for their invaluable collaboration!
The story is far from over, findings deserve further prospective and mechanistic research.
👇👇👇
https://t.co/B1ibMC3tT0

@DrJNaidoo @marinagarassino @HwakeleeMD @thenasheffect @DJPinato @FabianAckerMD @BRicciutiMD @FCitarellaMD @AminNassarMD @JordiRemon @BenjaminBesseMD @dplanchard @valentsant
@PoliclinCampus
@CampusBioMedico
@ImperialSandC
#LungCancer #NSCLC #Immunotherapy #Microbiome

[Rohit Malde @roxboxfix]

Management of colorectal cancer in older adults: an expert panel recommendation to guide daily clinical practice

(Lancet Gastroenterology & Hepatology, 2026)

[UroToday.com @urotoday]

First-line therapy determines bladder preservation in high-grade #NMIBC. @pcvblack @VanProstateCtr joins @UroDocAsh @UTMDAnderson to discuss bladder-preservation strategies in high-grade nonmuscle-invasive #BladderCancer, covering first-line optimization through second-line options. #WatchNow on UroToday > https://t.co/iDULprEan4

[Applied Radiation Oncology @Applied_RadOnc]

CHHiP vs PROFIT for Localized Prostate Cancer: A Retrospective Dosimetric Comparison of Organs at Risk

🔗 Find the full research article: https://t.co/IYf1mWsqGr

Moderate hypofractionation for localized prostate cancer has become a standard of care in many radiation therapy centers worldwide. Several fractionation and planning protocols exist, with CHHiP and PROFIT (60 Gy in 20 fractions) being 2 of the most commonly used. We retrospectively compared the doses received by organs at risk (OARs) using these 2 protocols.

#ProstateCancer #RadiationOncology #RadOnc #MensHealthMonth #MHM26 #CaseStudy #RadOncEd #MedEd

[European Urology @EUplatinum]

The latest EAU Guideline Summary Papers are now available on the European Urology website!

📄 European Association of Urology Guidelines on Testicular Cancer: Summary of the 2026 Guidelines by Anna Patrikidou et al – https://t.co/kxZ1jZvaHg
📄 European Association of Urology and American Society of Clinical Oncology Guidelines on Penile Cancer: A Summary of the 2026 Guidelines Update by Arie Parnham et al – https://t.co/JjRwF8u0sS
📄 Summary Paper on the 2026 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms by Michael Baboudjian, Massimiliano Creta et al – https://t.co/vJdjZqabCy
📄 European Association of Urology Guidelines on Urethral Strictures: Summary of the 2026 Guidelines. Update in Recommendations for Endoluminal Management of Male Anterior Urethral Strictures by Felix Campos-Juanatey et al – https://t.co/ruBOkCgWug

Explore the latest evidence-based recommendations and clinical updates in urology.
#Urology #EAU #EuropeanUrology

[ASTRO @ASTRO_org]

New in #practicalRO: MRI-based Atlas for Prostate Bed Recurrence after Radical Prostatectomy: Consistency of CTV Delineation with 7 Contouring Guidelines. https://t.co/YgnIU9w5Ns

[UroToday.com @urotoday]

Phase III #SunRISe2 trial compares gem-iDRS and cetrelimab to chemoradiation for #MIBC bladder preservation. @AndreaNecchi @MyUniSR joins @UroDocAsh @UTMDAnderson to discuss the phase III trial randomizing 518 muscle-invasive #BladderCancer patients refusing or unfit for cystectomy to Gem-iDRS plus cetrelimab vs chemoradiation. #WatchNow on UroToday > https://t.co/Sxi2xD0Yfx

[NonsparseOncologist @5_utr]

‼️ INDIBLADE: stage II/III (cT2-4aN0-2) MIBC -> induction ipilimumab plus nivolumab -> CRT

2-year bladder-intact event-free survival is 78% (0.67−0.9) 🤩

2-year overall survival was 96% (0.91−1)

Lots of bladders can be potentially spared!

https://t.co/LzTe72GYHD

[Giulia Marvaso @GiuliaMarvaso84]

@piet_ost @GiulioFrancoli1 @alongi_filippo @NicosiaMd @ChadTangMD Until a robust biological classification becomes available, we should rely on the clinical factors we already have in our hands

[RTOG Foundation @RTOGFoundation]

Check out the recording from this week's NRG-GU015 "ARCHER" study webinar:

[Erman Akkus @Erman_Akkus]

Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial @OncoAlert https://t.co/fiFLKKhBYV

[Paul Sargos @PaulSargos]

Out in @EUplatinum: managing late GU adverse events after prostate radiotherapy requires a truly multidisciplinary approach.

🔑 Better collaboration = Less controversy = Better survivorship outcomes...

🔽 🔽 🔽 🔽 🔽 🔽 🔽 🔽
https://t.co/ixuFLj9RED

[Jeff Ryckman @jryckman3]

@MuzamilArshad18 @CZamboglou @PaulSargos @TylerSbrt @davidjeinstein @HimanshuNagarMD @Soum_Roy_RadOnc @VedangMurthy @DrSpratticus @DrAndrewLoblaw @AmarUKishan @NicholasZaorsky @seanmmcbride Fantastic proof of concept coming, great read here.
https://t.co/w3n3D2XADS

I personally enjoy the 0.5 cm anatomically confined expansion around the DIL to receive traditional base dose with de-escalation of rest of gland @BrandonMahal

#RadTARGET #OncTwitter

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

@Prof_Nick_James with #RAD-IO trial durvalumab added to chemoradiation in #bladdercancer. Great to see the evolution of treatments for bladder preservation. @asco #asco26 @oncoalert @urotoday

[Darren Poon @DrDarrenPoon]

ASCO 2026 updates :
PROTEUS phase III: positive, but interpret carefully

High-risk localized/locally advanced PCa planned for RP + PLND + pre op & post op 6 mos ADT +/- Apalutamide
N=2109 | median FU 61.7 mo

Results
✅ pCR/MRD: 8.9% vs 1.0%
✅ 5-yr MFS: 78.2% vs 73.5%
✅ MFS HR 0.80, p=0.02
✅ EFS HR 0.71
⚠️ G3–4 AEs: 39.6% vs 31.0%
❌ No OS benefit yet

Key caveats
⚠️ Comparator was perioperative ADT, not RP alone
⚠️ Absolute 5-yr MFS gain only ~4.7%
⚠️ pCR/MRD improved, but still <10%
⚠️ Conventional-imaging MFS alone not significant
⚠️ PSMA PET use evolved during trial
⚠️ Post-op RT not standardized
⚠️ Risk of overtreatment in curative-intent disease

Take-home 💊
Landmark positive trial, but I would call it practice-informing, not blanket practice-changing. Most relevant for carefully selected very-high-risk surgical patients after MDT discussion.

Key unresolved question ❓

1. Whether this perioperative strategy is superior to contemporary RP with early salvage therapy,

2. How it should be positioned against RT + long-term ADT + ARPI-based intensification （STAMPEDE approach )

https://t.co/YPQfVgnVjQ

[Charles Jiang MD, MPH @CharlesJiangMD]

1/ #ASCO26 starts tomorrow. By Friday your feed will be full of survival curves, and the temptation will be everywhere: cross-trial/study comparison.

Before you do so, A few caveats worth keeping in mind

[PDBrown @PDBrownOnc]

🚨🚨 ASCO 2026 Final Results Randomized trial resected brain met Brachytherapy vs Post-Op SRS🚨
- Incredible Surg Bed Control with Brachy (↑↑OS as well)
- Surg bed recurrence 12% SRS vs 1% GammaTile